Mei Feng1,2, Jing Zhu1,2, Liqun Liang1,2, Ni Zeng1,2, Yanqiu Wu1,2, Chun Wan1,2, Yongchun Shen3,4, Fuqiang Wen1,2. 1. Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China. 2. Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital of Sichuan University, Chengdu, 610041, China. 3. Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China. shen_yongchun@126.com. 4. Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital of Sichuan University, Chengdu, 610041, China. shen_yongchun@126.com.
Abstract
BACKGROUND: Pleural effusion is one of the most common complications of lung adenocarcinoma and is diagnostically challenging. This study aimed to investigate the diagnostic performance of carcinoembryonic antigen (CEA), cytokeratin fragment (CYFRA) 21-1, and cancer antigen (CA) 19-9 for lung adenocarcinoma-associated malignant pleural effusion (MPE) through a validation study and meta-analysis. METHODS: Pleural effusion samples were collected from 81 lung adenocarcinoma-associated MPEs and 96 benign pleural effusions. CEA, CYFRA 21-1, and CA19-9 were measured by electrochemiluminescence immunoassay. The capacity of tumor markers was assessed with receiver operating characteristic curve analyses and the area under the curve (AUC) was calculated. Standard methods for meta-analysis of diagnostic studies were used to summarize the diagnostic performance of CEA, CYFRA 21-1, and CA19-9 for lung adenocarcinoma-associated MPE. RESULTS: The pleural levels of CEA, CYFRA 21-1, and CA19-9 were significantly increased in lung adenocarcinoma-associated MPE compared to benign pleural effusion. The cut-off points for CEA, CYFRA 21-1, and CA19-9 were optimally set at 4.55 ng/ml, 43.10 μg/ml, and 12.89 U/ml, and corresponding AUCs were 0.93, 0.85, and 0.81, respectively. The combination of CEA, CYFRA 21-1, and CA19-9 increased the sensitivity to 95.06%, with an AUC of 0.95. Eight studies were included in this meta-analysis. CEA showed the best diagnostic performance with pooled sensitivity, specificity, positive/negative likelihood ratio, and diagnostic odds ratio of 0.75, 0.96, 16.01, 0.23, and 81.49, respectively. The AUC was 0.93. CONCLUSIONS: CEA, CYFRA 21-1, and CA19-9 play a role in the diagnosis of lung adenocarcinoma-associated MPE. The combination of these tumor markers increases the diagnostic accuracy.
BACKGROUND:Pleural effusion is one of the most common complications of lung adenocarcinoma and is diagnostically challenging. This study aimed to investigate the diagnostic performance of carcinoembryonic antigen (CEA), cytokeratin fragment (CYFRA) 21-1, and cancer antigen (CA) 19-9 for lung adenocarcinoma-associated malignant pleural effusion (MPE) through a validation study and meta-analysis. METHODS:Pleural effusion samples were collected from 81 lung adenocarcinoma-associated MPEs and 96 benign pleural effusions. CEA, CYFRA 21-1, and CA19-9 were measured by electrochemiluminescence immunoassay. The capacity of tumor markers was assessed with receiver operating characteristic curve analyses and the area under the curve (AUC) was calculated. Standard methods for meta-analysis of diagnostic studies were used to summarize the diagnostic performance of CEA, CYFRA 21-1, and CA19-9 for lung adenocarcinoma-associated MPE. RESULTS: The pleural levels of CEA, CYFRA 21-1, and CA19-9 were significantly increased in lung adenocarcinoma-associated MPE compared to benign pleural effusion. The cut-off points for CEA, CYFRA 21-1, and CA19-9 were optimally set at 4.55 ng/ml, 43.10 μg/ml, and 12.89 U/ml, and corresponding AUCs were 0.93, 0.85, and 0.81, respectively. The combination of CEA, CYFRA 21-1, and CA19-9 increased the sensitivity to 95.06%, with an AUC of 0.95. Eight studies were included in this meta-analysis. CEA showed the best diagnostic performance with pooled sensitivity, specificity, positive/negative likelihood ratio, and diagnostic odds ratio of 0.75, 0.96, 16.01, 0.23, and 81.49, respectively. The AUC was 0.93. CONCLUSIONS:CEA, CYFRA 21-1, and CA19-9 play a role in the diagnosis of lung adenocarcinoma-associated MPE. The combination of these tumor markers increases the diagnostic accuracy.
Authors: Seung-Myoung Son; Hye-Suk Han; Jin Young An; Kang Hyeon Choe; Ki Man Lee; Ki Hyeong Lee; So-Seul Kim; Yong-Moon Lee; Ho-Chang Lee; Hyung Geun Song; Ok-Jun Lee Journal: Pathology Date: 2015-02 Impact factor: 5.306
Authors: Yoon Mi Shin; Jieun Yun; Ok-Jun Lee; Hye-Suk Han; Sung-Nam Lim; Jin Young An; Ki Hyeong Lee; Ki Man Lee; Kang Hyeon Choe Journal: Cancer Res Treat Date: 2014-04-22 Impact factor: 4.679
Authors: Penny F Whiting; Marie E Weswood; Anne W S Rutjes; Johannes B Reitsma; Patrick N M Bossuyt; Jos Kleijnen Journal: BMC Med Res Methodol Date: 2006-03-06 Impact factor: 4.615
Authors: Njanja Enz; Fernando Fragoso; Alexander Gamrekeli; Frank Lippek; Wolfgang Jungraithmayr Journal: J Thorac Dis Date: 2018-05 Impact factor: 2.895